Sign Out
Acute graft-versus-host disease
Adult: As prophylaxis in patients undergoing haematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor: In combination with a calcineurin inhibitor and methotrexate: 10 mg/kg (Max: 1,000 mg) via IV infusion over 60 minutes for 4 doses given on the day before transplantation and on days 5, 14, and 28 post-transplant. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: As prophylaxis in patients undergoing haematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor: In combination with a calcineurin inhibitor and methotrexate: 2-<6 years 15 mg/kg via IV infusion over 60 minutes given on the day before transplantation, followed by 12 mg/kg via IV infusion over 60 minutes given on days 5, 14, and 28 post-transplant. ≥6 years Same as adult dose. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: As prophylaxis in patients undergoing haematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor: In combination with a calcineurin inhibitor and methotrexate: 2-<6 years 15 mg/kg via IV infusion over 60 minutes given on the day before transplantation, followed by 12 mg/kg via IV infusion over 60 minutes given on days 5, 14, and 28 post-transplant. ≥6 years Same as adult dose. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Rheumatoid arthritis
Adult: For moderate to severe active cases in patients who had an inadequate response to at least one other DMARDs: As monotherapy or in combination with methotrexate or other DMARDs: For patients weighing <60 kg: 500 mg; 60-100 kg: 750 mg; >100 kg: 1,000 mg. Doses are given via infusion over 30 minutes every 2 weeks for 3 doses, then every 4 weeks thereafter. Reconsider the continuation of treatment if no adequate response is observed within 6 months of therapy. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Polyarticular juvenile idiopathic arthritis
Child: For moderate to severe active cases in patients who had an inadequate response to previous DMARD therapy: As monotherapy or in combination with methotrexate: ≥6 years weighing <75 kg: 10 mg/kg; 75-100 kg: 750 mg; >100 kg: 1,000 mg. Doses are given via infusion over 30 minutes every 2 weeks for 3 doses, then every 4 weeks thereafter. Reconsider the continuation of treatment if no adequate response is observed within 6 months of therapy. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Psoriatic arthritis
Adult: In patients who had an inadequate response to previous DMARD therapy: As monotherapy or in combination with methotrexate: For patients weighing <60 kg: 500 mg; 60-100 kg: 750 mg; >100 kg: 1,000 mg. Doses are given via infusion over 30 minutes every 2 weeks for 3 doses, then every 4 weeks thereafter. Reconsider the continuation of treatment if no adequate response is observed within 6 months of therapy. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Rheumatoid arthritis
Adult: For moderate to severe active cases in patients who had an inadequate response to at least one other DMARDs: As monotherapy or in combination with methotrexate or other DMARDs: 125 mg once weekly via SC inj. Doses may be initiated with or without an IV loading dose. If the treatment is initiated with a single IV infusion dose, administer the 1st 125 mg SC dose within 24 hours of the IV infusion, followed by 125 mg weekly SC inj thereafter. If switching from IV therapy to SC therapy, administer the 1st SC dose instead of the next scheduled IV dose. Reconsider the continuation of treatment if no adequate response is observed within 6 months of therapy. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Polyarticular juvenile idiopathic arthritis
Child: For moderate to severe active cases in patients who had an inadequate response to previous DMARD therapy: As monotherapy or in combination with methotrexate: ≥2 years weighing 10-<25 kg: 50 mg once weekly; 25-<50 kg: 87.5 mg once weekly; ≥50 kg: 125 mg once weekly. Doses may be initiated without an IV loading dose. Reconsider the continuation of treatment if no adequate response is observed within 6 months of therapy. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Subcutaneous
Psoriatic arthritis
Adult: In patients who had an inadequate response to previous DMARD therapy: As monotherapy or in combination with methotrexate: 125 mg once weekly via SC inj. Doses may be initiated without an IV loading dose. If switching from IV therapy to SC therapy, administer the 1st SC dose instead of the next scheduled IV dose. Reconsider the continuation of treatment if no adequate response is observed within 6 months of therapy. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Continue with Google